In this article, we will delve into the topic of Substituted phenylmorpholine, which has aroused great interest and debate in different areas. Substituted phenylmorpholine is a topic that has become the focus of attention of experts, academics and specialists in the field, due to its relevance and impact in different sectors. Over the last decades, Substituted phenylmorpholine has been acquiring greater importance and relevance, generating endless questions and concerns about its influence on today's society. In this article, we will analyze in detail and exhaustively the different facets of Substituted phenylmorpholine, with the aim of providing a complete and well-founded overview of this topic.

Substituted phenylmorpholines, or substituted phenmetrazines alternatively, are chemical derivatives of 2-phenylmorpholine or of the psychostimulant drug phenmetrazine.
Most such compounds act as releasers of monoamine neurotransmitters, and have stimulant effects. Some also act as agonists at serotonin receptors, and compounds with an N-propyl substitution act as dopamine receptor agonists.
A number of derivatives from this class have been investigated for medical applications, such as for use as anorectics or medications for the treatment of ADHD. Some compounds have also become subject to illicit use as designer drugs.[1][2][3][4]
| Substance | Structure | CAS # |
|---|---|---|
| 2-phenylmorpholine | 23972-41-0 | |
| 2-phenyl-3-methylmorpholine (phenmetrazine) | 134-49-6 | |
| 2-phenyl-3,4-dimethylmorpholine (phendimetrazine) | 634-03-7 | |
| 2-phenyl-5-methylmorpholine (isophenmetrazine) | 80123-66-6 | |
| 2-phenyl-3-ethylmorpholine (phenetrazine) | 100368-98-7 | |
| 2-phenyl-3-methyl-4-ethylmorpholine (phenmetetrazine) | 92196-09-3 | |
| 2-phenyl-3,5-dimethylmorpholine (PDM-35) | 1218345-44-8 | |
| 2-phenyl-3,6-dimethylmorpholine (6-methylphenmetrazine, 3,6-DMPM) | 92902-99-3 | |
| 2-phenyl-5,5-dimethylmorpholine (G-130) | 42013-48-9 | |
| 2-phenyl-3-methylmorpholin-5-one (fenmetramide) | 5588-29-4 | |
| 4-isopropyl-2-phenylmorpholine[5] | 23222-62-0 | |
| Fenbutrazate | 4378-36-3 | |
| Morazone | 6536-18-1 | |
| 2-Fluorophenmetrazine | 1533654-24-8 | |
| 3-fluorophenmetrazine (PAL-593) | 1350768-28-3 | |
| 4-Fluorophenmetrazine (PAL-748) | 1097796-73-0 | |
| 3-fluorophenetrazine | ||
| 3-chlorophenmetrazine (PAL-594) | 1097796-78-5 | |
| 3-Methoxyphenmetrazine | ||
| 2-Methylphenmetrazine | 1507705-48-7 | |
| 3-methylphenmetrazine (PAL-773) | 1350768-41-0 | |
| 4-methylphenmetrazine (PAL-747) | 1998216-41-3 | |
| 4-methylphendimetrazine | 1445576-23-7 | |
| 3-Iodophenmetrazine | ||
| 2-(4-Bromo-2,5-dimethoxyphenyl)morpholine (2C-B-morpholine) | ||
| 3,4-Methylenedioxyphenmetrazine[6] | ||
| Naphthylmetrazine (PAL-704) | ||
| 2-(thiophen-2-yl)-3-methylmorpholine | ||
| 2-(3-(Trifluoromethyl)phenyl)morpholine (flumexadol)[7] | 30914-89-7 | |
| Oxaflozane | 26629-87-8 | |
| Phenmetrazol | 1350768-19-2 | |
| N-Ethylphenmetrazol | 97630-98-3 | |
| (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol (radafaxine) | 106083-71-0 | |
| (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol (manifaxine) | 135306-39-7 | |
| PF-219,061[8] | 710654-74-3 | |
| PF-592,379 | 710655-15-5 | |
| OSU-6162 | 156907-84-5 | |
| LPH-5[9] | 2641630-97-7 | |
| 2-Methyl-3-phenylpiperidine | 70769-67-4 | |
| 2-Phenyl-3-methyl-thiomorpholine | ||
| 4-Methyl-5-phenyl-1,3-oxazolidine[10] | 42794-92-3 | |
| Picilorex | 62510-56-9 | |
| Butyltolylquinuclidine | ||
| 3-benzylmorpholine (3-BZM)[11] | 7684-27-7 | |
| 3-Benzhydrylmorpholine (3-BZHM) | 93406-27-0 |
Additional phenylmorpholines and their activities as monoamine releasing agents (MRAs) have been described.[12]
Table 3. Monoamine Release and 5HT2B Activity of a Series of Phenmetrazine Analogs Table 4. Comparison of the DA, 5-HT, and NE Releasing Activity of a Series of Phenmetrazine Analogs Table 5. Comparison of the DA, 5-HT, and NE Releasing Activity of a Series of (2S,5S)-5-methyl-2-phenylmorpolines